Robert Onder, MD
Allergy · Saint Louis, MONPI 1164533295
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 240 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,200 and has fallen 90.3% since, to $116 in 2025.
Across 240 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$612
- GSK$604
- AbbVie$544
- Regeneron Healthcare Solutions, Inc.$297
- Sanofi$269
- Pfizer$250
- plus $1K from 18 others
Across 368 payments — averaging $14,655 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2.8M
- Astrazeneca UK Limited$792K
- GSK$383K
- Teva Pharmaceuticals USA, Inc.$366K
- Chiesi USA, Inc.$363K
- Genentech, Inc.$283K
- plus $431K from 6 others
What the payments were for
- Food & beverage$3,79296%
- Education$1424%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 37 | $612 |
| GSK | 44 | $604 |
| AbbVie(2 entities) | 36 | $544 |
| Regeneron Healthcare Solutions, Inc. | 13 | $297 |
| Sanofi | 16 | $269 |
| Pfizer | 12 | $250 |
| Novartis | 13 | $221 |
| Teva Pharmaceuticals USA, Inc. | 16 | $165 |
| Kaleo, Inc. | 9 | $161 |
| Genentech USA, Inc. | 9 | $147 |
| Amgen | 6 | $100 |
| Optinose US, Inc. | 4 | $80 |
| Pharming Healthcare, Inc. | 4 | $72 |
| Aimmune Therapeutics, Inc. | 4 | $71 |
| Sanofi-aventis U.S. LLC | 1 | $65 |
| Merck | 4 | $64 |
| Grifols USA, LLC | 3 | $53 |
| LEO Pharma Inc. | 2 | $44 |
| Alk-abello, Inc | 2 | $35 |
| Biocryst US Sales Co., LLC | 1 | $19 |
| Bio Products Laboratory USA, Inc. | 1 | $19 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Circassia Inc. | 1 | $12 |
How this compares
Too few allergy providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 49 | $25,855 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,581 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $7,998 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $5,619 |
| Arnuity ElliptaFluticasone Furoate | 18 | $4,964 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,347 |
| Azelastine Hcl | 71 | $2,853 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $1,460 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,350 |
| Fluticasone Propionate | 73 | $915 |
| Montelukast Sodium | 85 | $559 |
| Omeprazole | 16 | $343 |
| Triamcinolone Acetonide | 13 | $235 |
| Levocetirizine Dihydrochloride | 18 | $221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $604 | $52,40098 claims |
| AstraZenecaSymbicort | $612 | $3,34715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Missourion file to place this against a meaningful peer group, so we don't.
Other allergy in Saint Louis
- Josie VitaleSaint Louis$10K
- Jeffrey WrightSaint Louis$7K
- Laura EssweinSaint Louis$6K
- Robert KocurSaint Louis$300
- Susan BerdySaint Louis$263
- Mark VandewalkerColumbia$15K
- Maria SabioKirkwood$15K
- Silvia HuebnerSpringfield$14K
- Lawrence LandwehrWarrensburg$6K
- Sanchayita TripathyRolla$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.